Nuveen LLC Has $643.46 Million Stock Position in Amgen Inc. $AMGN

Nuveen LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,965,903 shares of the medical research company’s stock after selling 86,287 shares during the period. Nuveen LLC’s holdings in Amgen were worth $643,460,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. Capital World Investors raised its holdings in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares during the period. Capital International Investors raised its holdings in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the period. Geode Capital Management LLC raised its holdings in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the period. Finally, Norges Bank acquired a new stake in Amgen during the 4th quarter worth approximately $2,164,162,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
• Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
• Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
• Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
• Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Truist Financial raised their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Barclays assumed coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Rothschild & Co Redburn raised their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.12.

Amgen Price Performance

NASDAQ:AMGN opened at $354.06 on Friday. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a fifty day simple moving average of $340.94 and a 200 day simple moving average of $345.65. The stock has a market capitalization of $191.09 billion, a PE ratio of 24.64, a P/E/G ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the business earned $4.90 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.